Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Biointerphases ; 15(6): 061003, 2020 11 13.
Article in English | MEDLINE | ID: mdl-33187397

ABSTRACT

The hydrophobically modified glycol chitosan (HGC) nanomicelle has received increasing attention as a promising platform for the delivery of chemotherapeutic drugs. To improve the tumor selectivity of HGC, here an avidin and biotin functionalization strategy was applied. The hydrodynamic diameter of the biotin-avidin-functionalized HGC (cy5.5-HGC-B4F) was observed to be 104.7 nm, and the surface charge was +3.1 mV. Confocal and structured illumination microscopy showed that at 0.1 mg/ml, cy5.5-HGC-B4F nanomicelles were distributed throughout the cytoplasm of MDA-MB-231 breast cancer cells after 2 h of exposure without significant cytotoxicity. To better understand the intracellular fate of the nanomicelles, entrapment studies were performed and demonstrated that some cy5.5-HGC-B4F nanomicelles were capable of escaping endocytic vesicles, likely via the proton sponge effect. Quantitative analysis of the movements of endosomes in living cells revealed that the addition of HGC greatly enhanced the motility of endosomal compartments, and the nanomicelles were transported by early and late endosomes from cell periphery to the perinuclear region. Our results validate the importance of using live-cell imaging to quantitatively assess the dynamics and mechanisms underlying the complex endocytic pathways of nanosized drug carriers.


Subject(s)
Chitosan/chemistry , Nanoparticles/chemistry , Avidin/chemistry , Biotin/chemistry , Carbocyanines/chemistry , Cell Line, Tumor , Cell Survival/drug effects , Drug Carriers/chemistry , Drug Carriers/toxicity , Endocytosis , Endosomes/metabolism , Humans , Microscopy, Fluorescence , Nanoparticles/metabolism , Nanoparticles/toxicity , Particle Size
2.
Oncotarget ; 7(38): 61107-61120, 2016 09 20.
Article in English | MEDLINE | ID: mdl-27531896

ABSTRACT

Matrix metalloproteinases (MMPs) play critical roles in cancer invasion and metastasis by digesting basement membrane and extracellular matrix (ECM). Much attention has focused on the enzymatic activities of MMPs; however, the regulatory mechanism of MMP expression remains elusive. By employing bioinformatics analysis, we identified a potential p53 response element within the MMP-14 promoter. Experimentally, we found that p53 can repress MMP-14 promoter activity, whereas deletion of this p53 response element abrogated this effect. Furthermore, we found that p53 expression decreases MMP-14 mRNA and protein levels and attenuates MMP-14-mediated cellular functions. Additional promoter analysis and chromatin immunoprecipitation studies identified a mechanism of regulation of MMP-14 expression by which p53 and transcription factor Sp1 competitively bind to the promoter. As the correlation between inflammation and cancer aggressiveness is well described, we next sought to evaluate if inflammatory cytokines could differentially affect p53 and MMP-14 levels. We demonstrate that interleukin-6 (IL-6) down-regulates p53 protein levels and thus results in a concomitant increase in MMP-14 expression, leading to enhanced cancer cell invasion and metastasis. Our data collectively indicate a novel mechanism of regulation of MMP-14 by a cascade of IL-6 and p53, demonstrating that the tumor microenvironment directly stimulates molecular changes in cancer cells to drive an invasive phenotype.


Subject(s)
Interleukin-6/metabolism , Matrix Metalloproteinase 14/metabolism , Neoplasms/metabolism , Tumor Suppressor Protein p53/metabolism , Animals , Basement Membrane/metabolism , Cell Line, Tumor , Cell Movement , Cytokines/metabolism , Disease Progression , Extracellular Matrix/metabolism , Female , Gene Deletion , Gene Expression Regulation, Neoplastic , Green Fluorescent Proteins/metabolism , Humans , Inflammation , Mice , Mice, Nude , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasm Transplantation , Promoter Regions, Genetic , Signal Transduction , Sp1 Transcription Factor/metabolism
3.
Front Biosci (Landmark Ed) ; 20(7): 1164-78, 2015 06 01.
Article in English | MEDLINE | ID: mdl-25961551

ABSTRACT

Development of inhibitors of matrix metalloproteinases (MMPs) has been fraught with challenges. Early compounds largely failed due to poor selectivity and bioavailability. Dose-limiting side effects, off-target interactions, and improperly designed clinical trials significantly impeded clinical success. As information becomes available and technology evolves, tools to combat these obstacles have been developed. Improved methods for high throughput screening and drug design have led to identification of compounds exhibiting high potency, binding affinity, and favorable pharmacokinetic profiles. Current research into MMP inhibitors employs innovative approaches for drug delivery methods and allosteric inhibitors. Such innovation is key for development of clinically successful compounds.


Subject(s)
Matrix Metalloproteinase Inhibitors/chemistry , Peptidomimetics/chemistry , Binding Sites , Computational Biology , Drug Delivery Systems/trends , Drug Discovery , Matrix Metalloproteinase Inhibitors/therapeutic use , Peptidomimetics/therapeutic use , Tetracycline/chemistry , Tetracycline/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...